Bio Protocol, a pioneering decentralized science (DeSci) platform, has successfully raised $6.9 million in a seed funding round to advance its mission of transforming biotechnology through AI and blockchain technologies. The round was led by Maelstrom Fund, the family office of BitMEX co-founder Arthur Hayes, with participation from Mechanism Capital, Animoca Brands, Zee Prime Capital, Panga Capital, Mirana Ventures, Foresight Ventures, Big Brain Holdings, and others.
Bio Protocol is developing an AI-native platform that enables scientists to convert their research into decentralized AI agents, known as BioAgents. These BioAgents can generate hypotheses, manage research funding, and commercialize discoveries through tokenized assets. The platform also facilitates the creation of BioDAOs, community-led research networks that fund and govern scientific innovations from universities, companies, and researchers worldwide.
The capital raised will support the expansion of Bio Protocol’s upgraded platform, Bio V2, which introduces enhanced fundraising tools, the BioXP rewards program, and advanced staking features. The company plans to roll out more BioAgents and IP tokens in the coming months, spanning critical therapeutic areas such as dermatology, microbiome health, brain health, and men’s health.
Arthur Hayes, Founder and CIO of Maelstrom Fund, commented, “If it works, it’s not just a launchpad – it’s the birth of an AI-native research market.” He added that Bio Protocol could become a “category-defining launchpad” for community-driven scientific research.
With this funding, Bio Protocol aims to democratize scientific research funding, making it more accessible to independent scientists and accelerating the pace of biotech innovation.
Read more on Tech Gist Africa:
ProRataAI Secures $40M Series B funding round
Figure AI has closed a Series C funding round exceeding US$1 billion
Rulebase Secures $2.1M Pre-Seed Funding to Revolutionize Fintech Back-Office Automation
